Fig. 1From: Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysisLiterature search and selection. The study procedure followed the PRISMA guidelinesBack to article page
